Baird Medical Investment Holdings Ltd

Baird Medical Investment Holdings Ltd

NNASDAQ:BDMD
0.11
USD
+0.02
(+17.68%)
41.82MMarket Cap
Mar 03Next Earn
Baird Medical Investment Holdings Ltd
NASDAQ:BDMD
(Nasdaq Stock Market)

Recent

price

0.11

P/E

ratio

- -

div

yld

- -

ROIC.AI

2021
2022
2023
2024
2025
TTM
USD
1.08
1.37
1.23
1.7
0.81
- -
Revenue per Share
0.39
0.49
0.41
0.57
-0.98
- -
Basic EPS, GAAP
0.15
-0.21
-0.14
-0.42
-0.05
- -
Free Cash Flow per Basic Share
0.21
- -
- -
- -
- -
- -
Dividend per Share
0.43
0.73
1.4
1.55
1.02
1.02
Book Value per Share
0.43
0.73
1.4
1.55
1.02
1.02
Tangible Book Value per Share
26
26
26
22
28
28
Basic Weighted Avg Shares
28
35
31
37
23
- -
Sales/Revenue/Turnover
47.23
42.77
40.22
41.35
-113.31
- -
Operating Margin (%)
1
1
1
1
1
- -
Depreciation Expense
10
13
11
12
-27
- -
Net Income, GAAP
19.22
12.03
13.76
10.57
- -
- -
Effective Tax Rate (%)
36.39
35.82
33.52
33.62
-121.04
- -
Profit Margin (%)
12
18
21
27
23
23
Working Capital
- -
1
2
4
6
6
LT Debt
15
26
36
40
31
31
Total Equity
- -
45.35
25.69
26.14
- -
- -
Return on Invested Capital (%)
- -
49.34
26.55
23.78
- -
- -
Return on Capital (%)
- -
60.85
34.19
33.03
-76.81
- -
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
17
17
13
LT Borrowings
3
6
6
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
26
27
31
Market Capitalization
194
97
42

Working Capital

USD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
61
61
55
Cash, Cash Equivalents & STI
3
2
- -
Accounts Receivable, Net
47
41
43
Inventories
1
1
1
Total Current Liabilities
35
35
32
Payables & Accruals
16
18
18
ST Debt
17
17
13
Deferred Revenue
1
1
1

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-21.47%
Free Cash Flow
- -
- -
-84.88%
Net Income, GAAP
- -
- -
-319.04%
Sales/Revenue/Turnover
- -
- -
-39.15%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

USD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
31
2024
- -
- -
37
2025
- -
- -
23

Semi-annual Earnings Per Share

USD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.41
2024
- -
- -
0.57
2025
- -
- -
-0.98

Semi-annual Dividends Per Share

USD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Business
Baird Medical Investment Holdings Limited (Nasdaq: BDMD) is a technology-driven medical device company that develops, manufactures, and sells minimally invasive instruments and devices for the treatment of thyroid diseases, including thyroid radiofrequency ablation (RFA) systems, microwave ablation (MWA) systems, and vascular access products; its flagship product, the Monopolar Radio-Frequency Ablation System (RFA 2000 series), utilizes vacuum-assisted technology for precise nodule detection and thermal ablation, while complementary offerings include the Bipolar Radiofrequency Ablation System (RFA 3000 series), microwave ablation generators, disposable electrodes, puncture needles, and biopsy needles. The company serves healthcare providers and patients seeking non-surgical alternatives to thyroidectomy, primarily targeting markets in China, with expanding operations in Asia and select international regions. Founded in 2013 and headquartered in Changsha, Hunan Province, China, Baird Medical operates through subsidiaries focused on research, production, and commercialization of ablation technologies in the interventional oncology segment. In recent developments, Baird Medical completed its initial public offering on Nasdaq in January 2024, raising approximately $43.5 million to fuel R&D, manufacturing expansion, and global market penetration; the company also secured strategic distribution partnerships in Southeast Asia and Europe during 2024-2025 to broaden access to its RFA platforms. Additionally, it launched enhancements to its MWA product line in mid-2025, incorporating AI-assisted imaging for improved procedural accuracy, and announced a manufacturing facility upgrade in Hunan Province to meet rising demand amid China's growing preference for minimally invasive thyroid treatments. These initiatives reflect Baird Medical's shift toward international scaling while reinforcing its leadership in ultrasound-guided thermal ablation solutions.

Company News

  • Baird Medical Enters South Korea Market through Strategic Distribution Partnership with ALLIS MED

  • Baird Medical and Alpmed Announce FDA 510(k) and EU CE Submissions for Irreversible Electroporation (IRE) System

  • Baird Medical Issues Statement Regarding Recent Share Price Volatility

  • Baird Medical Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

  • Baird Medical and China Resources Pharmaceutical Commercial Group Medical Devices Sign Strategic Distribution Agreement to Expand Access to Microwave Ablation in China

  • Baird Medical Announces Regulatory Milestones in Vietnam and Egypt, Expanding International Reach of Microwave Ablation Technology

  • Baird Medical Highlights Global Expansion and Strategic Progress During Third Quarter 2026

  • Baird Medical to Present at the H.C. Wainwright 28th Annual Global Investment Conference

  • Baird Medical Highlights Participation at CIRSE 2026 and Showcases Microwave Ablation Technology

  • Baird Medical Reports 25% Revenue Growth and Positive Net Income for Six Months Ended June 30, 2026

  • Baird Medical Investment (NASDAQ:BDMD) Trading Down 2.5% – Should You Sell?

  • Baird Medical Expands Global Microwave Ablation Footprint with Additional Product Registrations in Pakistan

  • Baird Medical and Alpmed Enter Strategic Partnership to Advance Irreversible Electroporation (IRE) Technology Globally

  • Baird Medical Announces First Microwave Ablation Procedures Using Its Technology in Vietnam and Argentina

  • Baird Medical Establishes Global Headquarters in New York City, Reinforcing Commitment to U.S. Commercial Expansion

  • Baird Medical Reports Full Year 2025 Financial Results and Provides Corporate Update

  • Baird Medical Advances Clinical Education with Expert-Led Workshops in Indonesia

  • Baird Medical Expands Global Reach with Regulatory Clearance in Argentina

  • Baird Medical Accelerates U.S. Expansion in Interventional Thyroidology at NASIT 2026

  • Baird Medical Accelerates Global Registration of AI-Driven Surgical Software